Relmada Therapeutics (RLMD) Interest Expenses (2014 - 2015)
Relmada Therapeutics (RLMD) reported Interest Expenses of $1172.0 for Q4 2015, up 6.74% year-over-year from $1098.0 in Q4 2014, and down 28.62% quarter-over-quarter from $1642.0 in Q3 2015.
Relmada Therapeutics (RLMD) Interest Expenses (2014 - 2015) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Interest Expenses data on file, last reported at $1172.0 in Q4 2015.
- Interest Expenses for Q4 2015 came in at $1172.0, up 6.74% year-over-year; the trailing twelve-month figure through Sep 2016 was $1172.0 (down 64.44% YoY), and the FY2015 annual result was $4922.0, up 100.8% from the prior year.
- Interest Expenses declined to $1172.0 in Q4 2015 per RLMD's latest filing, from $1642.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $435611.0 in Q2 2014 and troughed at $125.0 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1,172.00 |
| Dec 31, 2015 | 1,172.00 |
| Sep 30, 2015 | 1,642.00 |
| Sep 30, 2015 | 1,642.00 |
| Jun 30, 2015 | 431.00 |
| Jun 30, 2015 | 431.00 |
| Mar 31, 2015 | 125.00 |
| Mar 31, 2015 | 125.00 |
| Dec 31, 2014 | 1,098.00 |
| Dec 31, 2014 | 1,098.00 |
| Sep 30, 2014 | 3,268.00 |
| Sep 30, 2014 | 3,268.00 |
| Jun 30, 2014 | 435,611.00 |
| Jun 30, 2014 | 435,611.00 |
| Mar 31, 2014 | 123,800.00 |
| Mar 31, 2014 | 123,800.00 |